Phenylephrine hydrochloride

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1952

www.ebi.ac.uk

First approval year: 1952
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Phenylephrine hydrochloride
www.ebi.ac.uk

Molecular weight: 203.67
www.ebi.ac.uk

Structure (SMILES): CNC[C@H](O)c1cccc(O)c1.Cl
www.ebi.ac.uk

afrin 4 hour nasal spray
Afrin 4 hour nasal spray
biorphen
Biorphen
fenilfar
Fenilfar
fenox
Fenox
immphentiv
Immphentiv
mydfrin
Mydfrin
nazex
Nazex
neo synephrine
Neo-synephrine
neosynephrine
Neosynephrine
nostril
Nostril
nurofen sinus pain relief
Nurofen sinus pain relief
phenylephrine hydrochloride
Phenylephrine hydrochloride
phenylephrine hydrochloride component of advil congestion relief

And 19 more, listed on the interactive page.

advil congestion relief component phenylephrine hydrochloride
ADVIL CONGESTION RELIEF COMPONENT PHENYLEPHRINE HYDROCHLORIDE
biomydrin
BIOMYDRIN
biorphen
cyclomydril component phenylephrine hydrochloride
CYCLOMYDRIL COMPONENT PHENYLEPHRINE HYDROCHLORIDE
mydcombi component phenylephrine hydrochloride
MYDCOMBI COMPONENT PHENYLEPHRINE HYDROCHLORIDE
mydfrin
Mydfrin
nsc 757273
NSC-757273
omidria component phenylephrine hydrochloride
OMIDRIA COMPONENT PHENYLEPHRINE HYDROCHLORIDE
phenergan vc component phenylephrine hydrochloride
PHENERGAN VC COMPONENT PHENYLEPHRINE HYDROCHLORIDE
phenylephrine hcl
PHENYLEPHRINE HCL
phenylephrine hydrochloride
Phenylephrine hydrochloride
PHENYLEPHRINE HYDROCHLORIDE [EP MONOGRAPH]
PHENYLEPHRINE HYDROCHLORIDE [JAN]
PHENYLEPHRINE HYDROCHLORIDE [MART.]
PHENYLEPHRINE HYDROCHLORIDE [MI]

And 20 more, listed on the interactive page.

CAS registry numbers

61-76-7

ChEMBL ID: CHEMBL1200339
www.ebi.ac.uk

InChIKey: OCYSGIYOVXAGKQ-FVGYRXGTSA-N
www.ebi.ac.uk

FDA ingredient codes (UNII)

04JA59TNSJ

441279
657210
5284443

8164
221139

Applicant: HALEON US HOLDINGS
Approval date: 27 May 2010
Application number: NDA022565

Patents: 5
Designations: 0
Earliest recorded loss of exclusivity: 8 Aug 2044
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Over the counter

Administration routes

Oral
Parenteral
topical

Mechanism
Adrenergic receptor alpha-1 agonist
Action type
Agonist
Target
Adrenergic receptor alpha-1
Protein identifier
P25100
Mechanism
Adrenergic receptor alpha-1 agonist
Action type
Agonist
Target
Adrenergic receptor alpha-1
Protein identifier
P35348
Mechanism
Adrenergic receptor alpha-1 agonist
Action type
Agonist
Target
Adrenergic receptor alpha-1
Protein identifier
P35368

Open Targets mechanisms

Mechanism
Adrenergic receptor alpha-1 agonist
Action type
Agonist
Target
Adrenergic receptor alpha-1

Condition
Stomach Neoplasms
Highest recorded phase
2
Condition identifier
EFO:0000178
Subject identifier
D013274
Condition
Cardiovascular Diseases
Highest recorded phase
1
Condition identifier
EFO:0000319
Subject identifier
D002318
Condition
Infections
Highest recorded phase
1
Condition identifier
EFO:0000544
Subject identifier
D007239
Condition
Rhinitis, Allergic, Seasonal
Highest recorded phase
4
Condition identifier
EFO:0003956
Subject identifier
D006255
Condition
Arrhythmias, Cardiac
Highest recorded phase
1
Condition identifier
EFO:0004269
Subject identifier
D001145
Condition
Acute Lung Injury
Highest recorded phase
2
Condition identifier
EFO:0004610
Subject identifier
D055371
Condition
Hypotension
Highest recorded phase
4
Condition identifier
EFO:0005251
Subject identifier
D007022
Condition
Shock, Septic
Highest recorded phase
4
Condition identifier
EFO:0006834
Subject identifier
D012772
Condition
Common Cold
Highest recorded phase
4
Condition identifier
EFO:0007214
Subject identifier
D003139
Condition
Sinusitis
Highest recorded phase
4
Condition identifier
EFO:0007486
Subject identifier
D012852
Condition
Rhinitis, Vasomotor
Highest recorded phase
3
Condition identifier
EFO:0007533
Subject identifier
D012223
Condition
Rhinitis
Highest recorded phase
1
Condition identifier
EFO:0008521
Subject identifier
D012220
Condition
Hemorrhoids
Highest recorded phase
4
Condition identifier
EFO:0009552
Subject identifier
D006484
Condition
Pruritus
Highest recorded phase
4
Condition identifier
HP:0000989
Subject identifier
D011537
Condition
Nasal Obstruction
Highest recorded phase
4
Condition identifier
HP:0001742
Subject identifier
D015508
Condition
Mitral Valve Insufficiency
Highest recorded phase
1
Condition identifier
MONDO:0001298
Subject identifier
D008944
Condition
Cataract
Highest recorded phase
3
Condition identifier
MONDO:0005129
Subject identifier
D002386
Condition
Hypersensitivity
Highest recorded phase
4
Condition identifier
MONDO:0005271
Subject identifier
D006967
Condition
Respiratory Tract Infections
Highest recorded phase
3
Condition identifier
MONDO:0024355
Subject identifier
D012141

Condition identifier
EFO_0000319
Highest recorded phase
1
Condition identifier
EFO_0003956
Condition identifier
EFO_0004610
Highest recorded phase
2
Condition identifier
EFO_0005251
Condition identifier
EFO_0005856
Condition identifier
EFO_0006834
Condition identifier
EFO_0006834
Highest recorded phase
4
Condition identifier
EFO_0007214
Condition identifier
EFO_0007486
Condition identifier
EFO_0007533
Highest recorded phase
3
Condition identifier
EFO_0008521
Highest recorded phase
1
Condition identifier
EFO_0009373
Condition identifier
EFO_0009373
Highest recorded phase
4
Condition identifier
EFO_0009523
Highest recorded phase
3
Condition identifier
EFO_0009552
Condition identifier
EFO_0010072
Condition identifier
EFO_0010072
Highest recorded phase
4
Condition identifier
HP_0000989
Condition identifier
HP_0000989
Highest recorded phase
4
Condition identifier
HP_0001742
Condition identifier
HP_0001742
Highest recorded phase
4
Condition identifier
HP_0001945
Condition identifier
HP_0001945
Highest recorded phase
4
Condition identifier
HP_0002315
Condition identifier
HP_0002315
Highest recorded phase
4

And 21 more, listed on the interactive page.

Event
anaesthetic complication
Reports
78
Reporting signal score
221.701
Event
anaphylactic reaction
Reports
255
Reporting signal score
282.504
Event
anaphylactic shock
Reports
170
Reporting signal score
263.79
Event
asthma
Reports
187
Reporting signal score
157.272
Event
bradycardia
Reports
210
Reporting signal score
167.489
Event
bursitis
Reports
92
Reporting signal score
186.634
Event
cardiac arrest
Reports
182
Reporting signal score
255.701
Event
coeliac disease
Reports
80
Reporting signal score
192.042
Event
drug hypersensitivity
Reports
734
Reporting signal score
683.414
Event
food allergy
Reports
99
Reporting signal score
284.301
Event
generalised tonic-clonic seizure
Reports
85
Reporting signal score
107.976
Event
hepatic enzyme increased
Reports
183
Reporting signal score
160.444
Event
horner's syndrome
Reports
31
Reporting signal score
108.451
Event
hyperhidrosis
Reports
196
Reporting signal score
112.998
Event
hypersensitivity
Reports
254
Reporting signal score
129.41
Event
hypotension
Reports
390
Reporting signal score
204.992
Event
immunodeficiency
Reports
85
Reporting signal score
192.013
Event
lagophthalmos
Reports
41
Reporting signal score
161.052
Event
local anaesthetic systemic toxicity
Reports
75
Reporting signal score
354.297
Event
methaemoglobinaemia
Reports
110
Reporting signal score
365.001
Event
oxygen saturation decreased
Reports
129
Reporting signal score
107.741
Event
pain
Reports
454
Reporting signal score
128.939
Event
rheumatoid arthritis
Reports
236
Reporting signal score
173.479
Event
temperature regulation disorder
Reports
80
Reporting signal score
287.044
Event
therapeutic product effect incomplete
Reports
125
Reporting signal score
129.49

And 2 more, listed on the interactive page.

NCT00509964
clinicaltrials.gov
NCT00624650
clinicaltrials.gov
NCT00762567
clinicaltrials.gov
NCT00976209
clinicaltrials.gov
NCT01330017
clinicaltrials.gov
NCT01026961
clinicaltrials.gov
NCT01112462
clinicaltrials.gov
NCT02132312
clinicaltrials.gov
NCT02678234
clinicaltrials.gov
NCT02730364
clinicaltrials.gov
NCT03098680
clinicaltrials.gov
NCT03339726
clinicaltrials.gov
NCT04500899
clinicaltrials.gov
NCT05348980
clinicaltrials.gov

Dose: 40-100mcg; up to 200mcg
Route: Intravenous
How often: Every 1 to 2 minutes as needed; continuous infusion: every 4 hours

Dilute to 100 mcg/mL for bolus; dilute to 20 mcg/mL or 10 mcg/min for infusion; do not exceed 200 mcg/min
Do not dilute before administration if using 500 mcg/5 mL formulation

Hydrogen bond acceptors: 3
Hydrogen bond donors: 3
Polar surface area: 52.49
Calculated partition coefficient (ALogP): 0.65
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 3
Heavy atoms: 13
Molecular formula: C9H14ClNO2
Monoisotopic mass: 203.0713064
Natural product: No

0065-0343
0065-0349
0065-0359
0404-9931
0641-6142
0641-6188
0641-6189
0641-6229
0641-6245
0641-6246
0781-3422
0781-3458
0781-3466
0781-9226
0781-9227
0781-9228
14335-440
14335-441
14335-442
23155-620
25021-315
31722-343
31722-344
31722-345
36000-358

And 89 more, listed on the interactive page.

Recorded assays: 2,387
Active assays: 51

Confirmatory
Other
Screening
Summary

Cardiotonic Agents
id.nlm.nih.gov
Mydriatics
id.nlm.nih.gov
Sympathomimetics
id.nlm.nih.gov
Vasoconstrictor Agents
id.nlm.nih.gov
Nasal Decongestants
id.nlm.nih.gov
Adrenergic alpha-1 Receptor Agonists
id.nlm.nih.gov

Related records

Trials (213)

2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides
A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries
A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
A New More Efficient Cycloplegia Scheme
A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability
A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia
A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
A Randomized, Double-Blind, Trial Comparing Epinephrine Versus Phenylephrine as a Vasoconstrictor in Regional Anesthesia for Upper Extremity Surgery
A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects
A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo
Autoimmune Basis for Postural Tachycardia Syndrome
Best Regimen for Phenylephrine Administration During Cesarean Section
Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)
Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study

Approved for (7)

Allergic disease
Common cold
Hemorrhoid
Hypotensive disorder
Seasonal allergic rhinitis
Sinusitis
Toxic shock syndrome

In development for (9)

Acute lung injury Phase 2
Cardiac rhythm disease Phase 1
Cardiovascular disorder Phase 1
Cataract Phase 3
Congenital mitral valve insufficiency Phase 1
Gastric carcinoma Phase 2
Respiratory tract infectious disorder Phase 3
Rhinitis Phase 1
Vasomotor rhinitis Phase 3

Targets (3)

ADRA1A Adrenergic receptor alpha-1 agonist
ADRA1B Adrenergic receptor alpha-1 agonist
ADRA1D Adrenergic receptor alpha-1 agonist

Phenylephrine hydrochloride

Development status

Names and chemistry

Brand names (44)

Other names (45)

Identifiers

PubChem compound IDs (3)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (3)

Open Targets mechanisms

Investigated indications (19)

Open Targets indications (46)

Reported adverse events (27)

Trial references (14)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (4)

Pharmacologic actions

Related records

Trials (213)

Approved for (7)

In development for (9)

Other linked conditions (2)

Targets (3)